Screener
Beta Bionics BBNX Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323777
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total current assets | 231,034 | 267,905 |
| Property and equipment, net | 10,748 | 8,600 |
| Operating lease right-of-use asset | 5,816 | 6,627 |
| Long-term investments | 44,648 | 45,431 |
| Other long-term assets | 141 | 180 |
| Total assets | $292,387 | $328,743 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: |
Item 1. Financial Statements.
FAQ
- What is Beta Bionics's equity method investments?
- Beta Bionics (BBNX) reported equity method investments of $44.65M in Q2 2026.
- How has Beta Bionics's equity method investments changed year-over-year?
- Beta Bionics's equity method investments increased by 43.3% year-over-year, from $31.15M to $44.65M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Beta Bionics's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude